Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB: 2013 long-term incentive programme meets objectives and vests in full

Swedish Orphan Biovitrum AB ('s (publ) (Sobi™)
Board of Directors today announced that the company's 2013 long-term
incentive programme met the objectives set and will vest in full. The
total number of shares awarded to Sobi employees enrolled in the 2013
programme is 909,939.


A summary of the terms and conditions of Sobi's 2013 long-term
incentive program can be found on in Sobi's Annual Report 2015

About Sobi™
Sobi™ is an international specialty healthcare company dedicated to
rare diseases. Our mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily focused on Haemophilia, Inflammation and
Genetic diseases. We also market a portfolio of speciality and rare
disease products across Europe, the Middle East, North Africa and
Russia for partner companies. Sobi is a pioneer in biotechnology with
world-class capabilities in protein biochemistry and biologics
manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is
listed on NASDAQ Stockholm.

For more information please contact

Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice
Communications President, Head of Investor
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212
-579-0506, +46 8 697 2135


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.